📣 VC round data is live. Check it out!

Adverum Biotechnologies Valuation Multiples

Discover revenue and EBITDA valuation multiples for Adverum Biotechnologies and similar public comparables like Eli Lilly, Johnson & Johnson, AbbVie, Roche and more.

Adverum Biotechnologies Overview

About Adverum Biotechnologies

Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.


Founded

N/A

HQ

Employees

N/A

Website

N/A

Financials (FY)

Revenue:
Net Income:

Market Cap

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Adverum Biotechnologies Stock Performance

Adverum Biotechnologies has current market cap of .

Market CapPrice 1DPrice 1MPrice 3MPrice 12MEPS

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Adverum Biotechnologies Valuation Multiples

Adverum Biotechnologies Financial Valuation Multiples

As of May 14, 2026, Adverum Biotechnologies has market cap of —.

LTMLast FY202320242025202620272028

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Adverum Biotechnologies Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Valuation Multiples Across 230+ Verticals

Adverum Biotechnologies Competitors

Adverum Biotechnologies competitors include Eli Lilly, Johnson & Johnson, AbbVie, Roche, AstraZeneca, Novartis, Merck, Novo Nordisk, Amgen and Gilead Sciences.

Most Adverum Biotechnologies public comparables operate across Biopharmaceuticals, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Eli Lilly14.5x13.0x29.8x27.7x
Johnson & Johnson6.2x6.1x14.3x16.3x
AbbVie7.1x6.8x17.8x15.9x
Roche4.4x11.1x
AstraZeneca5.4x16.1x
Novartis5.7x5.9x14.1x14.2x
Merck5.0x4.9x10.9x12.1x
Novo Nordisk4.6x4.8x9.2x9.9x

This data is available for Pro users. Sign up to see all Adverum Biotechnologies competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Adverum Biotechnologies

Is Adverum Biotechnologies publicly listed?Yes, Adverum Biotechnologies is a public company listed on Munich Stock Exchange.
What is the stock symbol of Adverum Biotechnologies?Adverum Biotechnologies trades under AVU0 ticker.
When did Adverum Biotechnologies go public?Adverum Biotechnologies went public in 2014.
Who are competitors of Adverum Biotechnologies?Adverum Biotechnologies main competitors include Eli Lilly, Johnson & Johnson, AbbVie, Roche, AstraZeneca, Novartis, Merck, Novo Nordisk, Amgen, Gilead Sciences.
Is Adverum Biotechnologies profitable?No, Adverum Biotechnologies is not profitable.
How many companies Adverum Biotechnologies has acquired to date?Adverum Biotechnologies hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Adverum Biotechnologies has invested to date?Adverum Biotechnologies hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Adverum Biotechnologies

Lists including Adverum Biotechnologies

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial